Biocon Ventures into Weight-Loss Drug Market with Semaglutide Development

▴ Weight-Loss Drug Market with Semaglutide Development
Biocon's foray into the weight-loss drug market aligns with its significant investment in generics research and development, with a notable focus on peptides including those for weight-loss treatments.

Biocon, a prominent Indian drugmaker, is poised to enter the growing weight-loss drug market by developing its version of Novo Nordisk's highly successful Wegovy, with plans for clinical trials as early as next year if required. The move reflects Biocon's strategic positioning to tap into the anticipated growth of the obesity treatment market, projected to exceed $100 billion by the end of this decade.

CEO Siddharth Mittal emphasized Biocon's commitment to developing semaglutide for the Indian market, even if it necessitates conducting clinical trials. "We're striving to be one of the early players in the market, aiming for a launch in 2026 or shortly after," Mittal stated in an interview.

Biocon, headquartered in Bengaluru and heavily reliant on revenue from international markets like the United States, intends to initially introduce generic versions of weight-loss drugs in emerging markets such as Brazil, Mexico, and Saudi Arabia. Mittal noted that semaglutide will lose patent protection in these countries by 2026, prompting Biocon to engage in discussions with local manufacturers for supply partnerships.

The company's strategy involves seeking a waiver on clinical trials from Indian regulators, instead opting to submit bioequivalence studies demonstrating that their version of semaglutide yields an equivalent effect as the branded drug.

In addition to semaglutide, Biocon is also developing a version of tirzepatide, the active ingredient in Eli Lilly's obesity treatment Mounjaro and Zepbound. However, details regarding the timing and initial marketing strategy for tirzepatide were not disclosed.

The weight-loss drug market has demonstrated high demand, with Novo Nordisk's Wegovy and Eli Lilly's Mounjaro experiencing significant interest due to their effectiveness in helping patients achieve substantial weight loss. Wegovy, in particular, enabled participants in clinical trials to lose an average of 15% of their body weight, while Mounjaro led to an average loss of 18%. These drugs belong to the class of GLP-1 receptor agonists, which regulate blood sugar levels and slow digestion to promote a feeling of fullness.

Biocon's foray into the weight-loss drug market aligns with its significant investment in generics research and development, with a notable focus on peptides including those for weight-loss treatments. The company anticipates competition from other Indian pharmaceutical companies like Dr. Reddy's and Cipla, which are also exploring the development of their versions of Wegovy pending patent expiries.

Looking ahead, Biocon aims to capitalize on its development efforts by entering key markets globally, including India, Europe, and other emerging regions, with an array of weight-loss treatments tailored to meet the growing demand for effective obesity therapies.

Tags : #

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Dangers of Ultra-Processed Foods: A Wake-Up Call for Health Conscious IndiansMay 23, 2024
Can Intermittent Fasting Protect Against Liver Cancer? Here’s What the Science SaysMay 23, 2024
Easier, Faster Claims: The Impact of the National Claim Exchange PortalMay 23, 2024
Can Nightmares Predict Autoimmune Flares? Insights from a Groundbreaking StudyMay 23, 2024
Does Parent-Led Singing Improve Development in Preterm Infants? A Comprehensive StudyMay 22, 2024
Biohacking 101: Boosting Physical and Mental Well-beingMay 22, 2024
In a Miraculous Recovery a 13-Year-Old Girl in Delhi Awakens from Coma After Liver Transplant.May 21, 2024
Tackling Hypertension in South-East Asia: A Call to Action on World Hypertension DayMay 20, 2024
FSSAI's Crackdown on Harmful Fruit Ripening Practices: Ensuring Public Health and ComplianceMay 20, 2024
Uncovering the Presence of Microplastics in Human Blood and Their Health EffectsMay 18, 2024
Potential Risks of Meftal: What Consumers and Doctors Should KnowMay 18, 2024
Over-the-Counter Medications in India: A New Era of AccessibilityMay 18, 2024
DCGI Acts Against Overcharging: New Regulations for Blood CentresMay 17, 2024
Cattle as Hosts for Human and Bird Flu Viruses: A Potential Public Health ConcernMay 17, 2024
The Ethics of Live Surgery Broadcasts: NMC Seeks Public OpinionMay 17, 2024
Successful Removal of 3.7 KG Large Abdominal Tumor from 14-Year-Old Somalian Girl at KIMS Cuddles HospitalMay 16, 2024
iLEAD Sets a Precedent by Launching a Graphic Anthology Authored by Multimedia, Animation and Graphics Students May 16, 2024
Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT); Achieves significant advancement in Cancer Treatment to Enhance Quality of LifeMay 16, 2024
IIITH Announces Product Management Summer SchoolMay 16, 2024
Çelebi India's Delhi Cargo Terminal Successfully Handles Airbus H125 Helicopter ShipmentMay 16, 2024